Summary: Follow-up RAS data presented at ASCO
Professor Trond Buanes today gave a presentation titled ”RAS peptide
vaccination in resected pancreatic cancer patients - persistence of anti tumour
response and long term survival” at ASCO's (American Society of Clinical
Oncology) annual cancer meeting.
A follow-up study of 23 resected pancreatic cancer patients immunized in the
period from 1995 to 1998 with two different peptide vaccines targeting the RAS
mutation found in most instances of pancreatic cancer indicates that a long
lasting immune response is possible following immunization with a peptide
vaccine. Five patients that showed an immune response to the vaccine were still
alive in 2006, i.e. up to 10 years after the operation. Further analysis showed
that the immune system in three of these patients still remembered the RAS
vaccination.
The RAS vaccines are owned by Pharmexa. In addition, Pharmexa owns a number of
other proprietary cancer peptide vaccines, including GV1001 which is in phase
III clinical trials.
Hørsholm, June 4, 2007
Jakob Schmidt
Chief Executive Officer
Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525
Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45
4060 2558
Note to editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer, bone
degeneration and Alzheimer's disease, as well as serious infectious diseases
such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001,
a peptide vaccine that has entered phase III trials in pancreatic cancer and
phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine
Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA,
Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock
Exchange under the trading symbol PHARMX.
